{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06242470",
      "orgStudyIdInfo": {
        "id": "CP-MGC026-01"
      },
      "organization": {
        "fullName": "MacroGenics",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study of MGC026 in Participants With Advanced Solid Tumors",
      "officialTitle": "A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors"
    },
    "statusModule": {
      "statusVerifiedDate": "2026-02",
      "overallStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2024-03-06",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2028-05",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2028-10",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2024-01-12",
      "studyFirstSubmitQcDate": "2024-02-01",
      "studyFirstPostDateStruct": {
        "date": "2024-02-05",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2026-02-03",
      "lastUpdatePostDateStruct": {
        "date": "2026-02-05",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "MacroGenics",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study.\n\nParticipants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes."
    },
    "conditionsModule": {
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Non Small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Bladder Cancer",
        "Sarcoma",
        "Endometrial Cancer",
        "Melanoma",
        "Castration Resistant Prostatic Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Gastro-esophageal Cancer",
        "Pancreas Cancer",
        "Clear Cell Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Platinum-resistant Ovarian Cancer",
        "Breast Cancer",
        "Ovarian Cancer",
        "Esophageal Squamous Cell Cancer (SCC)"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SEQUENTIAL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 250,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Cohort 1",
          "type": "EXPERIMENTAL",
          "description": "MGC026 is a topoisomerase 1 inhibitor (TOP1i)-based ADC that targets B7-H3 administered IV every 3 weeks.",
          "interventionNames": [
            "Biological: MGC026 Dose Escalation"
          ]
        },
        {
          "label": "Cohort 2",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose Escalation"
          ]
        },
        {
          "label": "Cohort 3",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose Escalation"
          ]
        },
        {
          "label": "Cohort 4",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose Escalation"
          ]
        },
        {
          "label": "Cohort 5",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose Escalation"
          ]
        },
        {
          "label": "Cohort 6",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose Escalation"
          ]
        },
        {
          "label": "Expansion cohort 1",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose for Expansion"
          ]
        },
        {
          "label": "Expansion cohort 2",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose for Expansion"
          ]
        },
        {
          "label": "Expansion cohort 3",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose for Expansion"
          ]
        },
        {
          "label": "Expansion cohort 4",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose for Expansion"
          ]
        },
        {
          "label": "Expansion Cohort 5",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose for Expansion"
          ]
        },
        {
          "label": "Expansion Cohort 6",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: MGC026 Dose for Expansion"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "MGC026 Dose Escalation",
          "description": "Escalating doses of MGC026",
          "armGroupLabels": [
            "Cohort 1",
            "Cohort 2",
            "Cohort 3",
            "Cohort 4",
            "Cohort 5",
            "Cohort 6"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "MGC026 Dose for Expansion",
          "description": "MGC026 recommended dose for expansion",
          "armGroupLabels": [
            "Expansion Cohort 5",
            "Expansion Cohort 6",
            "Expansion cohort 1",
            "Expansion cohort 2",
            "Expansion cohort 3",
            "Expansion cohort 4"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest.",
          "timeFrame": "Throughout the study, up to 135 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Overall response rate in advanced solid tumors",
          "description": "The objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) is used to estimate the proportion of participants in the Response Evaluable population who achieve best overall response of complete response (CR) or partial response (PR) (called responders).\n\nComplete response (CR) is defined as disappearance of all target and non-target lesions.\n\nPartial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions, and no new lesions",
          "timeFrame": "Throughout the study, up to 135 weeks"
        },
        {
          "measure": "Duration of response (DoR) in advanced solid tumors",
          "description": "DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first. (RECIST 1.1) is used to classify responses.",
          "timeFrame": "Throughout the study, up to 135 weeks"
        },
        {
          "measure": "ORR rate in metastatic castration resistant prostate cancer (mCRPC)",
          "description": "The ORR per Prostate Cancer Working Group 3 (PCWG3) criteria is estimated as the proportion of participants in the Response Evaluable population who achieve best overall response of CR or PR (called responders).",
          "timeFrame": "Throughout the study, up to 135 weeks"
        },
        {
          "measure": "DoR in mCRPC",
          "description": "DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression, per PCWG3 criteria or death from any cause, whichever occurs first.",
          "timeFrame": "Throughout the study, up to 135 weeks"
        },
        {
          "measure": "Mean (standard deviation [SD]) of MGC026 total and conjugated antibody maximum serum concentration (Cmax)",
          "description": "The maximum concentration in the bloodstream at the end of the infusion.",
          "timeFrame": "Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4."
        },
        {
          "measure": "Mean (standard deviation [SD]) of MGC026 unconjugated payload Cmax",
          "description": "The maximum concentration in the bloodstream at the end of the infusion.",
          "timeFrame": "Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4."
        },
        {
          "measure": "Mean (SD) of MGC026 total and conjugated antibody area under the time concentration curve (AUC)",
          "description": "Calculated exposure to MGC026",
          "timeFrame": "Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1"
        },
        {
          "measure": "Mean (SD) of MGC026 unconjugated payload AUC",
          "description": "Calculated exposure to MGC026",
          "timeFrame": "Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1"
        },
        {
          "measure": "Number of participants who develop anti-MGC026 antibodies (immunogenicity)",
          "description": "Development of anti-MGC026 antibodies in the bloodstream",
          "timeFrame": "Day 1, Day 15, and Day 1 of every 21-day cycle, throughout the study, average of 1 year."
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults â‰¥ 18 years old, able to provide informed consent\n* Adequate performance and laboratory parameters\n* Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an archival tumor sample is not available. Participants with no available archival tissue sample who cannot safely undergo a fresh biopsy as determined by consultation between the sponsor and investigator are eligible\n* Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer.\n* Measurable disease per RECIST v1.1. Participants with metastatic CRPC without measurable disease are eligible.\n* Must be willing to use highly effective methods of birth control from the time of consent through 7 months after discontinuation of MGC026.\n* Not pregnant or breastfeeding.\n\nExclusion Criteria:\n\n* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score \\< 6), or carcinoma in situ.\n* Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment.\n* Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.\n* Prior treatment with any B7-H3 targeted agent for cancer or any ADC with a topoisomerase payload.\n* Prior autologous or allogeneic stem cell or solid organ transplant.\n* Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders.\n* Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.\n* Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.\n* Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.\n* History of primary immunodeficiency.\n* Major trauma or major surgery within 4 weeks of first study drug administration.\n* Known hypersensitivity to recombinant proteins.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Global Trial Manager",
          "role": "CONTACT",
          "phone": "301-251-5172",
          "email": "info@macrogenics.com"
        }
      ],
      "overallOfficials": [
        {
          "name": "Denise Casey, MD",
          "affiliation": "MacroGenics",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "The Angeles Clinic and Research Institute",
          "status": "RECRUITING",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90025",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "START Midwest",
          "status": "RECRUITING",
          "city": "Grand Rapids",
          "state": "Michigan",
          "zip": "49546",
          "country": "United States",
          "geoPoint": {
            "lat": 42.96336,
            "lon": -85.66809
          }
        },
        {
          "facility": "START-New York Long Island",
          "status": "RECRUITING",
          "city": "Lake Success",
          "state": "New York",
          "zip": "11042",
          "country": "United States",
          "geoPoint": {
            "lat": 40.77066,
            "lon": -73.71763
          }
        },
        {
          "facility": "Providence Cancer Institute",
          "status": "RECRUITING",
          "city": "Portland",
          "state": "Oregon",
          "zip": "97213",
          "country": "United States",
          "geoPoint": {
            "lat": 45.52345,
            "lon": -122.67621
          }
        },
        {
          "facility": "The University of Texas MD Anderson Cancer Center",
          "status": "RECRUITING",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "University of Texas Health Science Center at Houston",
          "status": "RECRUITING",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "START Mountain Region",
          "status": "RECRUITING",
          "city": "West Valley City",
          "state": "Utah",
          "zip": "84119",
          "country": "United States",
          "geoPoint": {
            "lat": 40.69161,
            "lon": -112.00105
          }
        },
        {
          "facility": "ICON Cancer Centre Wesley",
          "status": "RECRUITING",
          "city": "Auchenflower",
          "state": "Queensland",
          "zip": "4066",
          "country": "Australia",
          "geoPoint": {
            "lat": -27.47443,
            "lon": 152.99213
          }
        },
        {
          "facility": "ICON Cancer Centre Kurralta Park",
          "status": "RECRUITING",
          "city": "Kurralta Park",
          "state": "South Australia",
          "zip": "5037",
          "country": "Australia",
          "geoPoint": {
            "lat": -34.95142,
            "lon": 138.56702
          }
        },
        {
          "facility": "Austin Health- Olivia Newton John Cancer Center",
          "status": "RECRUITING",
          "city": "Heidelberg",
          "state": "Victoria",
          "zip": "3084",
          "country": "Australia",
          "geoPoint": {
            "lat": -37.75,
            "lon": 145.06667
          }
        },
        {
          "facility": "Oxford University Hospitals NHS Foundation Trust",
          "status": "RECRUITING",
          "city": "Oxford",
          "zip": "OX3 9DU",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.75222,
            "lon": -1.25596
          }
        },
        {
          "facility": "The Royal Marsden NHS Foundation Trust",
          "status": "RECRUITING",
          "city": "Sutton",
          "zip": "SM2 5PT",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.35,
            "lon": -0.2
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-13"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D009362",
          "term": "Neoplasm Metastasis"
        },
        {
          "id": "D000077195",
          "term": "Squamous Cell Carcinoma of Head and Neck"
        },
        {
          "id": "D002289",
          "term": "Carcinoma, Non-Small-Cell Lung"
        },
        {
          "id": "D055752",
          "term": "Small Cell Lung Carcinoma"
        },
        {
          "id": "D001749",
          "term": "Urinary Bladder Neoplasms"
        },
        {
          "id": "D012509",
          "term": "Sarcoma"
        },
        {
          "id": "D016889",
          "term": "Endometrial Neoplasms"
        },
        {
          "id": "D008545",
          "term": "Melanoma"
        },
        {
          "id": "D064129",
          "term": "Prostatic Neoplasms, Castration-Resistant"
        },
        {
          "id": "D002583",
          "term": "Uterine Cervical Neoplasms"
        },
        {
          "id": "D015179",
          "term": "Colorectal Neoplasms"
        },
        {
          "id": "D013274",
          "term": "Stomach Neoplasms"
        },
        {
          "id": "D010190",
          "term": "Pancreatic Neoplasms"
        },
        {
          "id": "D002292",
          "term": "Carcinoma, Renal Cell"
        },
        {
          "id": "D006528",
          "term": "Carcinoma, Hepatocellular"
        },
        {
          "id": "D001943",
          "term": "Breast Neoplasms"
        },
        {
          "id": "D010051",
          "term": "Ovarian Neoplasms"
        },
        {
          "id": "D000077277",
          "term": "Esophageal Squamous Cell Carcinoma"
        }
      ],
      "ancestors": [
        {
          "id": "D009385",
          "term": "Neoplastic Processes"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        },
        {
          "id": "D002294",
          "term": "Carcinoma, Squamous Cell"
        },
        {
          "id": "D002277",
          "term": "Carcinoma"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D006258",
          "term": "Head and Neck Neoplasms"
        },
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D002283",
          "term": "Carcinoma, Bronchogenic"
        },
        {
          "id": "D001984",
          "term": "Bronchial Neoplasms"
        },
        {
          "id": "D008175",
          "term": "Lung Neoplasms"
        },
        {
          "id": "D012142",
          "term": "Respiratory Tract Neoplasms"
        },
        {
          "id": "D013899",
          "term": "Thoracic Neoplasms"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D014571",
          "term": "Urologic Neoplasms"
        },
        {
          "id": "D014565",
          "term": "Urogenital Neoplasms"
        },
        {
          "id": "D052776",
          "term": "Female Urogenital Diseases"
        },
        {
          "id": "D005261",
          "term": "Female Urogenital Diseases and Pregnancy Complications"
        },
        {
          "id": "D000091642",
          "term": "Urogenital Diseases"
        },
        {
          "id": "D001745",
          "term": "Urinary Bladder Diseases"
        },
        {
          "id": "D014570",
          "term": "Urologic Diseases"
        },
        {
          "id": "D052801",
          "term": "Male Urogenital Diseases"
        },
        {
          "id": "D018204",
          "term": "Neoplasms, Connective and Soft Tissue"
        },
        {
          "id": "D014594",
          "term": "Uterine Neoplasms"
        },
        {
          "id": "D005833",
          "term": "Genital Neoplasms, Female"
        },
        {
          "id": "D014591",
          "term": "Uterine Diseases"
        },
        {
          "id": "D005831",
          "term": "Genital Diseases, Female"
        },
        {
          "id": "D000091662",
          "term": "Genital Diseases"
        },
        {
          "id": "D018358",
          "term": "Neuroendocrine Tumors"
        },
        {
          "id": "D017599",
          "term": "Neuroectodermal Tumors"
        },
        {
          "id": "D009373",
          "term": "Neoplasms, Germ Cell and Embryonal"
        },
        {
          "id": "D009380",
          "term": "Neoplasms, Nerve Tissue"
        },
        {
          "id": "D018326",
          "term": "Nevi and Melanomas"
        },
        {
          "id": "D012878",
          "term": "Skin Neoplasms"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D011471",
          "term": "Prostatic Neoplasms"
        },
        {
          "id": "D005834",
          "term": "Genital Neoplasms, Male"
        },
        {
          "id": "D005832",
          "term": "Genital Diseases, Male"
        },
        {
          "id": "D011469",
          "term": "Prostatic Diseases"
        },
        {
          "id": "D002577",
          "term": "Uterine Cervical Diseases"
        },
        {
          "id": "D007414",
          "term": "Intestinal Neoplasms"
        },
        {
          "id": "D005770",
          "term": "Gastrointestinal Neoplasms"
        },
        {
          "id": "D004067",
          "term": "Digestive System Neoplasms"
        },
        {
          "id": "D004066",
          "term": "Digestive System Diseases"
        },
        {
          "id": "D005767",
          "term": "Gastrointestinal Diseases"
        },
        {
          "id": "D003108",
          "term": "Colonic Diseases"
        },
        {
          "id": "D007410",
          "term": "Intestinal Diseases"
        },
        {
          "id": "D012002",
          "term": "Rectal Diseases"
        },
        {
          "id": "D013272",
          "term": "Stomach Diseases"
        },
        {
          "id": "D004701",
          "term": "Endocrine Gland Neoplasms"
        },
        {
          "id": "D010182",
          "term": "Pancreatic Diseases"
        },
        {
          "id": "D004700",
          "term": "Endocrine System Diseases"
        },
        {
          "id": "D000230",
          "term": "Adenocarcinoma"
        },
        {
          "id": "D007680",
          "term": "Kidney Neoplasms"
        },
        {
          "id": "D007674",
          "term": "Kidney Diseases"
        },
        {
          "id": "D008113",
          "term": "Liver Neoplasms"
        },
        {
          "id": "D008107",
          "term": "Liver Diseases"
        },
        {
          "id": "D001941",
          "term": "Breast Diseases"
        },
        {
          "id": "D010049",
          "term": "Ovarian Diseases"
        },
        {
          "id": "D000291",
          "term": "Adnexal Diseases"
        },
        {
          "id": "D006058",
          "term": "Gonadal Disorders"
        },
        {
          "id": "D018307",
          "term": "Neoplasms, Squamous Cell"
        },
        {
          "id": "D004938",
          "term": "Esophageal Neoplasms"
        },
        {
          "id": "D004935",
          "term": "Esophageal Diseases"
        }
      ]
    }
  },
  "hasResults": false
}